Marie Tosolini

Dr. Marie Tosolini

INSERM CRCT U1037, Toulouse, Occitanie, France

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2009 in Bioinformatics
Verified
Journal Article
Open access
PDF file
GBGabriela Bindea
Gabriela Bindea
BMBernhard Mlecnik
Bernhard Mlecnik
Hubert HacklHubert Hackl
Hubert Hackl
PCPornpimol Charoentong
Pornpimol Charoentong
MTMarie Tosolini
Marie Tosolini
JGJerome Galon
Jerome Galon
Summary: We have developed ClueGO, an easy to use Cytoscape plug-in that strongly improves biological interpretation of large lists of genes. ClueGO integrates Gene Ontology (GO) terms as well as KEGG/BioCarta pathways and creates a functionally organized GO/pathway term network. It can analyze one or compare two lists of genes and comprehensively visualizes functionally grouped terms. A one-click update option allows ClueGO to automatically download the most recent GO/KEGG release at any time. ClueGO provides an intuitive representation of the analysis results and can be optionally used in conjunction with the GOlorize plug-in. Availability:http://www.ici.upmc.fr/cluego/cluegoDownload.shtml Contact:jerome.galon@crc.jussieu.fr Supplementary information: Supplementary data are available at Bioinformatics online.

29 September 2006 in Science
Verified
Journal Article
Closed access
PDF file
JGJerome Galon
Jerome Galon
ACAnne Costes
Anne Costes
FSFatima Sanchez-Cabo
Fatima Sanchez-Cabo
AKAmos Kirilovsky
Amos Kirilovsky
BMBernhard Mlecnik
Bernhard Mlecnik
FPFranck Pagès
Franck Pagès
The role of the adaptive immune response in controlling the growth and recurrence of human tumors has been controversial. We characterized the tumor-infiltrating immune cells in large cohorts of human colorectal cancers by gene expression profiling and in situ immunohistochemical staining. Collectively, the immunological data (the type, density, and location of immune cells within the tumor samples) were found to be a better predictor of patient survival than the histopathological methods currently used to stage colorectal cancer. The results were validated in two additional patient populations. These data support the hypothesis that the adaptive immune response influences the behavior of human tumors. In situ analysis of tumor-infiltrating immune cells may therefore be a valuable prognostic tool in the treatment of colorectal cancer and possibly other malignancies.

1 October 2013 in Immunity
Verified
Journal Article
Closed access
GBGabriela Bindea
Gabriela Bindea
BMBernhard Mlecnik
Bernhard Mlecnik
MTMarie Tosolini
Marie Tosolini
AKAmos Kirilovsky
Amos Kirilovsky
MWMaximilian Waldner
Maximilian Waldner
JGJerome Galon
Jerome Galon

14 February 2011 in Cancer Research
Verified
Journal Article
Open access
PDF file
MTMarie Tosolini
Marie Tosolini
AKAmos Kirilovsky
Amos Kirilovsky
BMBernhard Mlecnik
Bernhard Mlecnik
TFTessa Fredriksen
Tessa Fredriksen
SMStéphanie Mauger
Stéphanie Mauger
JGJerome Galon
Jerome Galon
The tumor microenvironment includes a complex network of immune T-cell subpopulations. In this study, we systematically analyzed the balance between cytotoxic T cells and different subsets of helper T cells in human colorectal cancers and we correlated their impact on disease-free survival. A panel of immune related genes were analyzed in 125 frozen colorectal tumor specimens. Infiltrating cytotoxic T cells, Treg, Th1, and Th17 cells were also quantified in the center and the invasive margin of the tumors. By hierarchical clustering of a correlation matrix we identified functional clusters of genes associated with Th17 (RORC, IL17A), Th2 (IL4, IL5, IL13), Th1 (Tbet, IRF1, IL12Rb2, STAT4), and cytotoxicity (GNLY, GZMB, PRF1). Patients with high expression of the Th17 cluster had a poor prognosis, whereas patients with high expression of the Th1 cluster had prolonged disease-free survival. In contrast, none of the Th2 clusters were predictive of prognosis. Combined analysis of cytotoxic/Th1 and Th17 clusters improved the ability to discriminate relapse. In situ analysis of the density of IL17+ cells and CD8+ cells in tumor tissues confirmed the results. Our findings argue that functional Th1 and Th17 clusters yield opposite effects on patient survival in colorectal cancer, and they provide complementary information that may improve prognosis. Cancer Res; 71(4); 1263–71. ©2011 AACR.

20 February 2011 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BMBernhard Mlecnik
Bernhard Mlecnik
MTMarie Tosolini
Marie Tosolini
AKAmos Kirilovsky
Amos Kirilovsky
ABAnne Berger
Anne Berger
GBGabriela Bindea
Gabriela Bindea
JGJerome Galon
Jerome Galon
Purpose: The prognosis of patients with colorectal cancer has sometimes proved uncertain; thus, the prognostic significance of immune criteria was compared with that of the tumor extension criteria using the American Joint Committee on Cancer/International Union Against Cancer–TNM (AJCC/UICC-TNM) staging system.Patients and Methods: We studied the intratumoral immune infiltrates in the center of the tumor and in the invasive margin of 599 specimens of stage I to IV colorectal cancers from two independent cohorts. We analyzed these findings in relation to the degree of tumor extension and to the frequency of recurrence.Results: Growth of the primary tumor and metastatic spread were associated with decreased intratumoral immune T-cell densities. Sixty percent of patients with high densities of CD8+cytotoxic T-lymphocyte infiltrate presented with stage Tis/T1 tumor, whereas no patients with low densities presented with such early-stage tumor. In patients who did not relapse, the density of CD8 infiltrates was inversely correlated with T stage. In contrast, in patients whose tumor recurred, the number of CD8 cells was low regardless of the T stage of the tumor. Univariate analysis showed that the immune score was significantly associated with differences in disease-free, disease-specific, and overall survival (hazard ratio [HR], 0.64, 0.60, and 0.70, respectively; P < .005). Time-dependent receiver operating characteristic curve analysis illustrated the predictive accuracy of the immune parameters (c-index = 65.3%, time-dependent c-index [Cτ] = 66.5%). A final stepwise model for Cox multivariate analysis supports the advantage of the immune score (HR, 0.64; P < .001; Cτ = 67.9%) compared with histopathologic features in predicting recurrence as well as survival.Conclusion: Assessment of CD8+cytotoxic T lymphocytes in combined tumor regions provides an indicator of tumor recurrence beyond that predicted by AJCC/UICC-TNM staging.

10 December 2009 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
FPFranck Pagès
Franck Pagès
AKAmos Kirilovsky
Amos Kirilovsky
BMBernhard Mlecnik
Bernhard Mlecnik
MAMartin Asslaber
Martin Asslaber
MTMarie Tosolini
Marie Tosolini
JGJerome Galon
Jerome Galon
Purpose: Many patients who present with early-stage colorectal cancer (International Union Against Cancer TNM stages I and II) are nevertheless at high risk of relapse. We hypothesized that intratumoral immune reaction could influence their prognosis. Patients and Methods: The intratumoral immune reaction was investigated in 29 tumors by large-scale real-time polymerase chain reaction. Cytotoxic (CD8) and memory (CD45RO) T cells were quantified by immunohistochemical analyses of tissue microarrays from the center (CT) and the invasive margin (IM) of the 602 tumors from two independent cohorts. The results were correlated with tumor recurrence and patient survival. Results: Patients with a strong infiltration of CD45RO+ cells in the tumor exhibited an increased expression of T-helper 1 and cytotoxicity-related genes. Densities of CD45RO+ and CD8+ cells in tumor regions (CT/IM) classified the patients into four distinct prognostic groups based on the presence of high density of each marker in each tumor region. The four groups were associated with dramatic differences in disease-free, disease-specific, and overall survival (all P < .0001). Five years after diagnosis, only 4.8% (95% CI, 0.6% to 8.8%) of patients with high densities of CD8+ plus CD45RO+ cells had tumor recurrence, and 86.2% (CI, 79.4% to 93.6%) survived. In contrast, the tumor recurred in 75% (95% CI, 17% to 92.5%) of patients with low densities of these cells, and only 27.5% (95% CI, 10.5% to 72%) survived (all P < .0001). Multivariate analyses showed that the immune criteria had independent effects on the rates of complete remission and survival. Conclusion: The combined analysis of CD8+ plus CD45RO+ cells in specific tumor regions could provide a useful criterion for the prediction of tumor recurrence and survival in patients with early-stage colorectal cancer.